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RETROSPECTIVE COMPARISON OF ALLOGENEIC STEM CELL TRANS- 
PLANTATION (SCT) IN PEDIATRIC PATIENTS UTILIZING PERIPHERAL 
BLOOD STEM CELLS (PBSC) VS BONE MARROW (BM) 
D,ev,'t, R.E.; Jacobso/31z, D.; K!et~d, M. Hemato/ogy-O,colog),-Tl'a,s- 
plmzt, ClaildreT~ '.rMemorial Hospital, C,~icago, IL. 
G-CSF mobilized PBSC are increasingly used as a source of 
helnatopoietic stem cells (HSC) for allogeneic SCT. Randomized 
studies in adults uggest benefits using PBSC related to early engraft- 
ment, reduced acute to ,  city and lack of increase in acute graft-vs- 
host disease (GVIID) despite the increase in T-cell dose adminis- 
tered with PBSC. Reports comparing chronic GVHD following 
SCT using PBSC vs BM have varied. Pediatl'ic (vs adult) recipients 
of allogeneic SCT have lower rates of acute and chronic GVHD, as 
well as reduced risk for acute to,city. We report a retrospective 
comparison of 76 pediau'ic patients with hematologic malignancies, 
15 received allogeneic PBSC from matched related (n= 11) or unre- 
lated donors CURD, n= 4) fl'om 3/2000 through 9/2002.61 received 
BM from matched related (n= 5i) or URD (n= 10) from 6/I992 
through 7/2002. PBSC donors received G CSF (10 mcg/kg/d x 4d) 
for tISC mobilization. Cytoreduction therapy for all patients was 
fracdonated total body irradiation (150 cGy x8 = 1200 cGy) + etopo- 
side (1000 rag/m2 xl) + cyclophosphamide (60 mg/kg x3). Growth 
factor support with G-CSF was routinely administered beginning on 
day +7. GVHD prophylaxis was similarly uniform (Cyclosporine A 
and reduced medaotrexate-days 1, 3 & 6). All URD recipients also 
received ATG (20 mg/kg x4 post SCT) and 11 URD recipients 
received tacrolimus substituted for Cyclosporine A. Patients treated 
with other cytoreducdon protocols or alternative GVHD prophylax- 
is regimens were excluded. Although retrospective, non-randomized 
and longer follow-up exists for the BM recipients, this analysis of 
PBSC vs BM in Pediatric allogeneic SCT recipients suggests results 
similar to larger andomized studies in adults-reduced I00 day mor 
talky without increased acute GVHD. Despite shorter follow-up, 
chronic GVHD was significantly greater in PBSC recipients. Longer 
follow-up is required to better assess true rates of recurrence and 
chronic GVHD after SCT with PBSC. A randomized trial will 
require multi-center participation. Allogeneic SCT using PBSC in 
pediatric patients appears to be an acccptable alternative toBM. 
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OUTCOME OF PEDIATRIC PATIENTS WHO UNDERGO HEMATOPOITIC 
STEM CELL TRANSPLANTATION (HSCT) FOR MONOSOMY 7 AND 
OTHER CYTIOGENETICALLY ABNORMAL MYELODYSPLASTIC SYN- 
DROMES (MDS) OR ACUTE NON-LYMPHOBLASTIC LEUKEMIA (ANLL) 
A SINGLE INSTITUTION EXPERIENCE 
Kh'tzel, ~i.; Jacobsoh~z, D.; D,e'l'st, R. C'hildveJzs l~leT, oHal Hospital, 
673icago, IL. 
From March 1992 to September 2002 sixteen patients were 
diagnosed with cytogenetical]y abnormal MDS/ANLL. Our 
objective is to report the outcome of these patients after they 
received an HSCT. Of the 16 patients, there 9 males and 7 
females. Mean age at diagnosis is 7.3 years, median 6.6 (1.0-16.6), 
Race Caucasian (n=9), Afi'ican ganerican (n=2), tlispanic (n=4) and 
1 other. Type of HSCT Unrelated umbilical cord (n=8), matched 
sibling (n-3), matched unrelated (n=4) and autologous with 4-HC 
purged marrow (n=l). Eleven patients had the diagnosis of MDS 
and 5 ANLL; 8 were primary and 8 were seconda, T. The cytoge- 
netic abnormalities include: Monosomy 7 (n=10), Monosomy 5 
(n=l), Monosomy 5, 7 (n=l) Trisomy 8 (n=l), t (6-9) (n=2) and t 
(8-16) (n=1). Ablation was TBI 150cGy BID x 8 doses, VP-16 
(VP) 1000mg/m2/day xl day and Cycophosphamide (Cy) 60 
mg/kg/day x 3 days (n=9); Busulfan (Bid) hng/kg/dose x 16 doses, 
VP, Cy (n=5); and Fludarabine 25mg/m2/day x 6 days, BU 
lmg/kg/dose x 8 and ATG 40mg/kg/day x 5 clays n=(2). Cell 
doses infused MNC x 108/kg mean 0.3 (median 0.5, range 0.1- 
7.1) CD34+ cells x i06/kg mean 0.6, (median 1.8, range 0.3-16.2) 
GVHD prophylaxis included: CSA/MTX/ATG (n=10), 
CSA/MTX (n=3), CSA (n=2), none (n=l). The time to ANC>500 
was mean 31days (median 22.5days), to platelets of >20.0 mean 
36.5 days (median 37days) and platelets >50.0 mean 55 days 
(median 53 days). Grade I/ i i  GVHD develop in (n=7) Grade 
III/IV (n=2), no GVHD (n=7). No chronic GVHD (n=13), Limit 
ed (n=i) Extensive (n=l) unknown (n=l). Other complications 
included: Interstitial pneumonia (n=l) Toxic Epidermolysis (n=l) 
Fungai Infection (n=2) Hemorragic Cystitis (n=2). The Event free 
survival at 4 years post transplant is 55% (95% CI 0.4-.07). 
HSCT for patients with MDS/ANLL with cytogenetic abnormal- 
ities can be an effective treatment, even when alternative donor 
sources are used. 
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215 
NSI AND NS2 SUBPOPULATIONS OF BONE MARROW NATURAL SUP- 
PRESSOR CELLS 
Belyaev, N.; Bogd, nmv, ,4.; Savv,lidi, P.; Zaki~ya, ova, G.: TMdieva, 
R. f ,  stitute qf l~loleczdat" Biology mid Bioche'mist/3~, Atmaty, IGtzakhsta,. 
Natural suppressor (NS) cells are hcterogenic population of 
early bone marrow haelnopoietic precm'sors that play an impor- 
tant role in chronic GVHD and also in suppression ofNK activi- 
ty during tumor development. Proceeding on numerous litera- 
tm'e data we have suggested that there are at least two NS 
subpopulations: NS1 and NS2 which are stimulated with IL-2 
and IFNg or IL-3 and GM-CSF respectively. In this work we 
have tried to prove the existence of these two NS subpopulations. 
The bone marrow cells (BMC) of CBA mice were cultivated in 
concentration of 2x106/ml under standard cell culture conditions 
for 48 h. NS activity was judged on the ability of BMC culture 
supernatants to inhibit myeloma cell proliferation by MT~F-test. 
We determined NS activity induced with IL-2 (NS1), IL-3 
(NS2) or spontaneous ( NS). NK activity of mononuclear spleen 
cells was estimated by eytoto~c assay. TGFb was determined by 
ELISA. We have shown that sNS activity- was not obselwed while 
NS1 and NS2 activity was determined and apparendy it was con- 
nected with TGFb; production because of antiproliferative activi- 
ty of supernatants corelated with TGFb concentration. Further- 
more these supernatants inhibited NK activity for certain. Earlier 
we have shown that the most sNS activity is revealed in BMC 
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isopicnic Fraction IV (1.090 g/ml) separated on gradient of per- 
coll. As it turned out both induced NS activities were discovered 
in this Fraction IV. In this work we were successful to obtain two 
separate ceil fractions with floating density of 1.080 and 1.090 
g/ml. The former fraction strictly showed only NS1 activity but 
the latter one showed only NS2 activity. The role of every NS 
subpopulations in different immunological processes has to be 
clarified. 
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IMMUNOTHERAPY AND SINGLE AGENT CHEMOTHERAPY IN 
METASTATIC BREAST CANCER 
Dicke, K.; Blumenschein, G.; Shermn,, 3/I. Stem Cell Lab, Arlington 
Cancer Center, Arli,gton, TA: 
In metastatic breast cancer there is a high response rate greater 
than 50% after high dose (HD) chemotherapy with autologous 
stem cell support in chemotherapy sensitive disease. However, the 
median duration of response is limited to 18 months. We have 
treated patients with multiple chemotherapy regimens after HD 
and demonstrated anincrease in the median progression free sur- 
vival to 42 months. We have studied the role of immunotherapy 
added to a single agent chemotherapy program in thirteen 
patients predominantly with minimal residual disease as demon- 
strated with our cytokeratin analysis in the bone marrow. The 
innnunotherapy rogram consisted of GM-CSF 250 micrograms 
subcutaneous daily for three days followed by 1.5 miliion Interna- 
tional units of Interlenldn-2/m2 subcutaneous daily for ten days. 
Treatment was initiated after patients failed to respond to single 
agent chemotherapy. Treatments were given on a monthly basis. 
Of the thirteen patients there were nine responders. The median 
duration was 14 months. Seven of the nine patients are still 
responding. Interestingly, the nine responders are all Her-2 posi- 
tive and treated with Herceptin on a weekly basis, also during 
immunotherapy treatment. To,city is minimal and this treatment 
does not interfere with quality of life. 
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REPAIR OF INFARCTED HEART BY EMBRYONIC STEM CELLS 
Feng, Z.~; Bayat, H.2; Bttrhan, K.2; DeMaria, A.2; Carrier, E. I 
1. Bo,e Ala'Jwow Transplant, Universi U of CA, &m Diego, La rid&, 
CA; 2. Universi U of CA, San Diego, La Jolla, CA. 
The objective of this work is to determine the efficacy and safe- 
ty of Embryonic Stem (ES) cell therapy in routine heart infarct 
model as well as to establish functional improvement in the heart 
function following cellular therapy. Methods: 12 C57B1/6J female 
mice (3 months old) underwent left coronary ligation under gen- 
eral anesthesia with isoftorane. Enhanced yellow fluorescent pro- 
tein (EGFP) marked murine ES cells (R1/129) and ES-CCE Cell 
without marker fluorescence protein were injected into the bor- 
der area of the infarcted zone of routine heart. Serial frozen sec- 
tions of hearts were made at 24 hours, 1 and 2 weeks post injec- 
tion. EGFP staining was double detected using Zeiss 
epifluorescent microscope and determined by immunohistochem- 
istry using anti-GFP antibody. GFP, MEF2 and GATA-4 pro- 
tein expression were detected using western blot assay by anti 
rabbit GFP, MEF2 and GATA-4 antibody. Cardiac function was 
determined by echocardiography and exercise testing using 
motor-driven treadmill. Results: Initial operative survival of 
infarcted mice was 100%. Zeiss epifluorescent microscope 
showed GFP signal in infarcted cardiac area in mice injected with 
EGFP-ES and not in ES-CCE injected mice. Bright field 
microscopy of the same sections howed similar results using 
anti-GFP immunostaining. Western blot showed that GFP pro- 
tein was detectable in ES-injected infarcted mice after 2 weeks 
but not in ES-CCE injected mice, however, MEF-2 and GATA- 
4 proteins were detectable in both ES cells injected mice. Echo 
performed at one week after infarction revealed large infarcts in 
all surviving infarcted animals. Exercise treadmill (ETT) per- 
formed 1 week after infarction showed 80% reduction in exercise 
tolerance compared to sham controls ( ame operation but no 
coronary ligation) and un-operated controls. Conclusions: 1- 
Implantation of ES cell into the infarcted region s feasible by 
direct injection into the periphery of the infarcted zone. 2-With 
new anesthesia and surgical skills, we are able to generate large 
infarcts in mice that lead to reduction in cardiac fnnction easily 
assessed by echo and ETT. 3-Further studies are underway to 
assess the role of ES cell therapy on cardiac function and remod- 
eling. 
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RECONSTITUTION OF VASCULAR ENDOTHELIUM FOLLOWING 
TRANSPLANTATION OF BONE MARROW DERIVED STEM CELLS 
Fleming, ~{LH.; Jiang, S., Afe,toulis, M.; Bauma,n, C.I.; Wong, 
M.H.; Bailey, A.S. OregoT~ Health & &'iences University, Po'rtla,d, OR. 
Bone marrow derived (BM) cells have recently been shown to 
participate in angiogenesis following shelnic injury. It remains 
unknown whether the vascular damage associated with lethal does 
of irradiation provides the signals necessary to induce BM cells to 
differentiate into endothelium. To address this question, 5E6 
unfi:actionated BM cells from male C57BL/6-EGFP mice were 
transplanted into lethally irradiated (1200 cGy) C57BL/6 female 
recipients. Examination of the liver of recipient mice at 5 days 
post transplant revealed only rare GFP+ cells. However, by day 
14, GFP+ donor cells were readily detected within the liver 
including the portal veins (PV), central veins, hepatic arteries and 
the microvasculature. The presence of donor derived cells within 
the intima of the vascular tissue was confirmed by in situ 
hybridization using a Y chromosome specific probe. A mean of 
38% of the PV demonstrated > 3 GFP+ cells incorporated into 
the intima of the vessel wall (~10% of luminal cells per cross sec- 
tion). By 6 months post transplant, >50% of the PV contained 
GFP+ cells. Luminal GFP+ cells evaluated by confocal 
microscopy co-expressed both CD31 and yon Willebrand factor 
(vWF) but did not express CD45. A similar donor derived 
endothelial phenotype was found in vasculature of the lungs and 
the gut. To determine if donor derived endothelial cells could be 
generated from the HSC compartment, c-kit + Sca-l + Lin- 
(KSL) cells were sorted from the BM of adult GFP mice and 
transplanted into irradiated recipients. Evaluation of the liver of 
these chimeric recipients howed donor derived GFP+ CD3 I+ 
vVVF+ CD45- cells in a dose dependent manner with a frequency 
similar to that observed following the transplantation f an equiv- 
alent dose of nnffactionated BM. Donor derived endothelial cells 
were also readily detected in the lungs and the gut. These results 
indicate that KSL cells can be induced to give rise to multilineage 
hematopoiesis and contribute xtensively to vascular endothelium 
in the irradiated transplant recipient. 
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UMBILICAL CORD BLOOD CELLS ENGRAFT AND DIFFERENTIATE IN 
NEURAL TISSUES AFTER HUMAN TRANSPLANTATION 
Kurtzberg, Jd; Kosaras, B.2; Stephens, Cd; Snyder, E.y..2 1. Pedian'ics, 
Duke University Medical Center, Durham, NC, 2. Harvard 3/Iedicul 
School, Boston, ~L't. 
Bone marrow transplantation can prevent progression of neuro- 
logic damage caused in infants and young children with inborn 
errors of metabolism if the transplant procedure is performed 
before extensive neurologic dan, age has occurred. It has previous- 
ly been shown that donor derived hematopoietic cells migrate into 
brain to deliver enzyme to neighboring host, enzyme deficient 
cells. However, differentiation ofmarrow derived donor cells into 
cells of neural or glial origin has not been definitively demonstrat- 
ed. Over the past 6 years, 20 pts with Krabbe disease (globoid 
leukodystrophy) have been transplanted atDuke Medical Center 
with unrelated umbilical cord blood (UCB). Five pts, transplanted 
as neonates have derived significant benefit from the procedure 
with increasing neurocognitive development, correction of nerve 
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